4,995
edits
Obesity: Difference between revisions
From W8MD weight loss and sleep centers
→Chapter 9: Supplements and Medications for Weight Loss
| Line 59: | Line 59: | ||
* Hysterectomy for weight loss | * Hysterectomy for weight loss | ||
==Chapter 9: [[Supplements and | ==Chapter 9: [[Supplements]] and [[Meal replacements]] for weight loss== | ||
* Overview of [[weight loss supplements]] | * Overview of [[weight loss supplements]] | ||
* Effectiveness and risks of weight loss medications and | * Effectiveness and risks of weight loss supplements | ||
==Chapter 10: Prescription [[weight loss medications]]== | |||
For people who struggle with obesity, medication can be a useful tool in their weight loss journey. However, not all medications are created equal. Some can be effective, while others may have dangerous side effects. In this article, we will discuss the different types of anti-obesity medications, their current FDA status, and their efficacy. | |||
* Prescription [[weight loss medications]], including [[Wegovy]] / [[Ozempic]], [[Mounjaro]], [[Liraglutide]] (brand names:[[Saxenda]] / [[Victoza]]), [[Contrave]], [[Plenity]], [[Phentermine/topiramate]], [[Phentermine]], [[Alli]], [[Phentermine]], and [[Metformin]] | * Prescription [[weight loss medications]], including [[Wegovy]] / [[Ozempic]], [[Mounjaro]], [[Liraglutide]] (brand names:[[Saxenda]] / [[Victoza]]), [[Contrave]], [[Plenity]], [[Phentermine/topiramate]], [[Phentermine]], [[Alli]], [[Phentermine]], and [[Metformin]] | ||
* [{Weigh loss injections]] - [[Glucagon-like peptide-1 (GLP-1)]] are peptide incretin hormones involved in blood sugar control. [[Semaglutide]], a GLP-1 analogue, administered once weekly, is more effective than [[exenatide]]. [[Semaglutide]] ([[Ozempic]], [[Wegovy]]) and [[tirzepatide]] ([[Mounjaro]]) are the most promising candidates for weight management in the anti-obesity market. In 2021, one review concluded that "Currently, gut peptide analogues such as semaglutide [...] and [...] tirzepatide are the furthest advanced in clinical development." A further review in 2022 found that these two peptides are "the most promising candidates for the upcoming battle in the anti-obesity market." [[Semaglutide]] has been approved for medical use in the US and the European Union for weight management in adults, sold under the brand name [[Wegovy]]. On the other hand, [[tirzepatide]] has been approved under the name [[Mounjaro]] for type-2 diabetes and is being studied, and fast tracked for [[weight loss]]. | |||
=Part 4: Health Benefits of Weight Loss= | =Part 4: Health Benefits of Weight Loss= | ||
